Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | STAT1 | P42224 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | ACR | P10323 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13230169 | 0.84 | ALOX5AP (0.58) | ALOX5APMAPTTP53SMN1; SMN2NPC1 | |
| SCHEMBL480281 | 0.83 | ALOX5AP (0.70) | ALOX5APMAPTTP53SMN1; SMN2NPC1 | |
| SCHEMBL480229 | 0.83 | ALOX5AP (0.70) | ALOX5APMAPTTP53SMN1; SMN2NPC1 | |
| SCHEMBL13262245 | 0.79 | ALOX5AP (0.59) | ALOX5APMKNK1MKNK2 | |
| SCHEMBL480222 | 0.78 | ALOX5AP (0.67) | ALOX5APMAPK1MKNK1MKNK2 | |
| SCHEMBL480248 | 0.77 | ALOX5AP (0.57) | ALOX5APMAPTPOLBSMN1; SMN2MAPK1 | |
| SCHEMBL480257 | 0.77 | ALOX5AP (0.77) | ALOX5APMKNK1MKNK2 | |
| SCHEMBL709581 | 0.76 | ALOX5AP (0.56) | ALOX5APMAPTTP53SMN1; SMN2NPC1 | |
| SCHEMBL480217 | 0.76 | ALOX5AP (0.60) | ALOX5APMAPTPOLBSMN1; SMN2MKNK1 | |
| SCHEMBL10197150 | 0.76 | ALOX5AP (0.70) | ALOX5APMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440672-B2 | Diphenyl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2064204-B1 | INHIBITORS OF 5 -LIPOXYGENASE ACTIVATING PROTEIN ( FLAP) | MERCK SHARP & DOHME (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168076-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | ALOX5AP 14/4885MAPT 4793/4885POLB 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.